CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 4 enrolled
Drug / intervention
Intravenous (IV) citrullinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02314689
NCT02314689Phase 1Completed
CompareCT.gov

A Dose Escalation Study of Intravenous L-citrulline in Steady-state Sickle Cell Disease

Suvankar Majumdar·interventional·Posted Dec 11, 2014·Updated Sep 3, 2019

In Brief

A Phase 1 clinical trial evaluating Intravenous (IV) citrulline for Sickle Cell Disease. Completed, enrolled 4 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the maximum tolerated dose, safety and pharmacokinetics of an investigational drug, intravenous (IV) citrulline, in subjects in steady-state sickle cell disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 11, 2014
Enrollment StartJan 1, 2015
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.6 years ago

Interventions

Intravenous (IV) citrullinedrug